Aarti Pharmalabs Limited has officially submitted its Annual Secretarial Compliance Report for the financial year ending March 31, 2026. This report, issued by M/s. Mehta & Mehta, Company Secretaries in Practice, confirms the company’s adherence to various regulatory requirements. The document was filed with the BSE Ltd. and the National Stock Exchange of India Limited on May 26, 2026.
Annual Secretarial Compliance Report Submitted
Aarti Pharmalabs Limited has filed its Annual Secretarial Compliance Report for the financial year that concluded on March 31, 2026. The report was prepared by the firm M/s. Mehta & Mehta, Practising Company Secretaries, and was submitted to both the BSE Ltd. and the National Stock Exchange of India Limited on May 26, 2026. This filing is a mandatory requirement under Regulation 24A of the SEBI (LODR) Regulations, 2015.
Scope of the Compliance Report
The Practising Company Secretaries, Mehta & Mehta, have thoroughly examined all provided documents and explanations from Aarti Pharmalabs Limited. Their review also encompassed filings made to the stock exchanges and information available on their respective websites, as well as any other relevant documentation. The examination covered compliance with the Securities and Exchange Board of India Act, 1992, and the Securities Contracts (Regulation) Act, 1956, along with associated regulations, circulars, and guidelines.
Key Regulations Assessed
The report specifically details compliance with several critical SEBI regulations, including:
- Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
- Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.
- Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.
The company was found to be in compliance with the applicable Secretarial Standards (SS) issued by the Institute of Company Secretaries India (ICSI). All applicable policies under SEBI Regulations have been adopted with board approval and are regularly reviewed and updated. The company also maintains a functional website with timely dissemination of corporate information and has ensured no director is disqualified under Section 164 of the Companies Act, 2013.
Related Party Transactions and Disclosures
Regarding Related Party Transactions, the report notes that prior approval was obtained from the Audit Committee for most transactions. An exception was made for transactions amounting to Rs. 5.16 lakhs, for which ratification was obtained subsequently. The company has also provided all required disclosures under Regulation 30 of the SEBI LODR Regulations, 2015, within the prescribed time limits. No significant non-compliance was observed during the review period.
Assumptions and Limitations
The report clarifies that the responsibility for compliance with applicable laws and the authenticity of furnished information lies with the management of Aarti Pharmalabs Limited. The review conducted by Mehta & Mehta is based on the examination of relevant documents and information, and it does not constitute an audit or an expression of opinion on the future viability or effectiveness of the company’s operations.
Source: BSE
